In the News
Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
Gateway for Cancer Research accelerates practice-changing clinical trials to cancer research by harnessing the unrelenting passion of the research community and empowering patients to triumph over their disease. All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.
Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
Patients with non-microsatellite instability-high metastatic colorectal cancer had better survival rates from the botensilimab and balstilimab combination.
Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
The combination of botensilimab and balstilimab combination showed a survival benefit, regardless of RECIST 1.1 responses, among patients with metastatic, heavily pretreated, microsatellite stable colorectal cancer.
Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
The combination of botensilimab and balstilimab elicited durable responses and provided overall survival benefits in patients with microsatellite stable metastatic colorectal cancer that is resistant to chemotherapy and/or immunotherapy.
New Strategies for Targeting CTLA-4 Emerge
In 2011, the development of ipilimumab, a novel antibody targeting the CTLA-4 immune checkpoint, helped launch the modern era of anticancer immunotherapy.
Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
For many patients, there is no greater sense of promise than cancer immunotherapy and it is often the first inquiry we receive. Of course, the concept of cancer immunotherapy is not new, dating back 150 years when William B.